Novo Nordisk (NYSE: NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced ...

A blockbuster diabetes and weight-loss drug might be doing more than controlling blood sugar—it could also be protecting the ...

A unique business structure gives LifeMD access to the growing GLP-1 marketplace that can help boost the heavily shorted stock price. Read an analysis of LFMD here.

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in ...

A new study suggests that popular weight loss medications could significantly benefit patients awaiting kidney transplants.

A massive U.S. study found diabetics on semaglutide (Ozempic’s active ingredient) had up to 70% lower risk of ...

At this year’s Morningstar Investment Conference in Chicago, Morningstar equity researchers will share their insights on the ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

The actress shares her weight loss journey, revealing she hopes to shed 40 pounds with Ozempic after struggling with body ...

FAIR Health data released this month showed more than 2% of adult patients now take a GLP-1 drug to treat overweight or ...

Semaglutide injections are helping you lose weight-but if yours isn't FDA-approved (and a lot of them aren't), it could be ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...